Today we shared additional clinical data from Part 1 of our ongoing SUMMIT trial evaluating bezuclastinib in patients with #NonAdvSM. Stop by our poster at #EHA2024 today to learn more. You can also read the press release here https://bit.ly/4c1CLOO and find the poster on our website https://bit.ly/4coyc0Z.
Cogent Biosciences
Biotechnology Research
Waltham, Massachusetts 11,003 followers
Precision therapeutics for genetically defined diseases. Real solutions for real challenges.
About us
Cogent Biosciences is a biotechnology company focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Cogent’s lead program, bezuclastinib, is designed to selectively and potently inhibit exon 17 mutations found within the KIT receptor tyrosine kinase, including KIT D816V. KIT D816V is responsible for driving a rare and serious condition called Systemic Mastocytosis, and exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Bezuclastinib has already exhibited promising early clinical activity and safety in a Phase 1/2 trial in patients with advanced GIST and also has the potential to fill an unmet need for patients living with Systemic Mastocytosis.
- Website
-
http://www.cogentbio.com
External link for Cogent Biosciences
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Waltham, Massachusetts
- Type
- Public Company
- Founded
- 2014
- Specialties
- gastrointestinal stromal tumors (GIST), Oncology, Systemic Mastocytosis, and kinase inhibitors
Locations
-
Primary
Get directions
275 Wyman Street
3rd Floor
Waltham, Massachusetts 02451, US
-
Get directions
4840 Pearl East Circle
Suite 100
Boulder, Colorado 80301, US
Employees at Cogent Biosciences
Updates
-
The Cogent team is excited about the scientific content at #EHA2024 in Madrid and we’re thrilled to participate in discussions with the hematology community. Come by our booth to learn more!
-
-
Our G&A team enjoyed an evening filled with fun, laughter, and friendly competition. Moments like these remind us of the strong bonds we share and the amazing people we work with every day. 🎳 #TeamOuting #WorkFun #GATeam
-
-
We’re participating in the #JefferiesHealthcare conference this week. Tune in to the fireside chat webcast tomorrow at 2:30pm ET. Register and listen here https://bit.ly/3KmVM28
-
-
We made it to Chicago! Come meet the team in the exhibit hall. You can also check out today’s PEAK lead-in update poster here https://bit.ly/45dYArV and read the details from our press release https://bit.ly/4dWlZlx. #GIST #raredisease
-
-
We’re thrilled to welcome Cole Pinnow as our new Chief Commercial Officer! Read more here. https://bit.ly/3yvW2cz
-
-
Today we shared positive updated lead-in data from our ongoing Phase 3 PEAK trail with bezuclastinib in combination with sunitinib in GIST patients. The data are being presented at #ASCO24. Read more here https://bit.ly/4dWlZlx.
-
-
Cogent is excited to engage with attendees at the American Initiative in Mast Cell Diseases (AIM) meeting this weekend in Boston. We’re proud to support this important educational event for the patient and clinical communities. Come meet the team at our Clinical Trial Basecamp to learn more. #ASM #NonAdvSM #MastCellDiseases #mastocytosis
-
-
Earlier this week we reported our first quarter 2024 financial results. Read the full announcement here. https://bit.ly/4dr74Q5
-